Experimental and Therapeutic Medicine-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=804973, encodeId=700a8049e341, content=出版费已经交了，大概啥时候见刊？有前辈可以告诉一下大概时间吗？网上查不到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Tue Jul 28 23:11:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885503, encodeId=0fc58855039d, content=审稿速度:3.0 偏重的研究方向：细菌 经验分享：1. 2020.4.20投稿； 2.6月20第一次催稿，两天后回复说在同行评审； 3.8月1号第二次催稿，未收到回复，8月12号直接收到peer-review comments ；要求45天内revision 4.9.8号收到Awaiting response to peer reviewer comments催稿信，于是9,9给杂志社回复了 response to peer reviewer comments 5. 9.14收到acception: We are pleased to inform you that the above manuscript has been provisionally accepted for publication in Experimental and Therapeutic Medicine. The submission should be considered to be formally accepted upon the receipt of proofs. The manuscript will be sent for production shortly. Once production has been completed, the page proofs of the manuscript will be sent to you with any minor revisions for your consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e65e5274913, createdName=1482e854m23(暂无昵称), createdTime=Tue Sep 15 16:21:34 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800885, encodeId=b56d80088552, content=请问这个杂志怎么转钱过去？我填了一个费用chart，但是没看到他给我账号。请问出版的前辈们怎么给他转账？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Thu Jul 02 11:57:24 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602161, encodeId=14c26021616c, content=非常奇怪，我一个月内发了4封邮件，带有校稿附件。他都收不到，还让我给他发proof。这是为什么？我163的邮箱没问题啊，我给别的邮箱发都可以啊。我给他发咨询邮件他就说没收到proof。有遇到这样问题的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Sat Jun 13 10:04:10 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123540, encodeId=b76f21235404b, content=快5个月了，怎么还没有消息，中间催了一次，说外审中，时间不确定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221005/d231bd6bc894445e8ddf64ddbeb135f0/a97cb00fc8be4fe49a0630e6db9fcb3e.jpg, createdBy=7dfe8143237, createdName=ms4000002043504686, createdTime=Mon Apr 03 19:36:15 CST 2023, time=2023-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=925369, encodeId=bb0d9253692b, content=终于收到了交费表格，我真的是...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Thu Feb 18 23:38:28 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161585, encodeId=a194216158511, content=07.10投稿，07.12送审，8.23小修，9.04接收，中间修改了4次proof，10.07交了版面费，等online中，虽然是公认的水刊，但是是篇meta分析，能发表就已经很满足了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=01451679623, createdName=叮咚_MH, createdTime=Sun Oct 08 17:55:33 CST 2023, time=2023-10-08, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801171, encodeId=7ec08011e1cc, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：去年10月投的稿今年三四月份小修。后面proof的修改发现编辑会非常仔细的修改文章从作者单位格式问题到内容部分非常认真，觉得IF会再升一升，但确实这个杂志发文量也比较大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Sat Jul 04 11:17:25 CST 2020, time=2020-07-04, status=1, ipAttribution=)]

2020-07-28 蒙住双眼做实验

出版费已经交了，大概啥时候见刊？有前辈可以告诉一下大概时间吗？网上查不到。

129 31

展开31条回复

[GetPortalCommentsPageByObjectIdResponse(id=804973, encodeId=700a8049e341, content=出版费已经交了，大概啥时候见刊？有前辈可以告诉一下大概时间吗？网上查不到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Tue Jul 28 23:11:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885503, encodeId=0fc58855039d, content=审稿速度:3.0 偏重的研究方向：细菌 经验分享：1. 2020.4.20投稿； 2.6月20第一次催稿，两天后回复说在同行评审； 3.8月1号第二次催稿，未收到回复，8月12号直接收到peer-review comments ；要求45天内revision 4.9.8号收到Awaiting response to peer reviewer comments催稿信，于是9,9给杂志社回复了 response to peer reviewer comments 5. 9.14收到acception: We are pleased to inform you that the above manuscript has been provisionally accepted for publication in Experimental and Therapeutic Medicine. The submission should be considered to be formally accepted upon the receipt of proofs. The manuscript will be sent for production shortly. Once production has been completed, the page proofs of the manuscript will be sent to you with any minor revisions for your consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e65e5274913, createdName=1482e854m23(暂无昵称), createdTime=Tue Sep 15 16:21:34 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800885, encodeId=b56d80088552, content=请问这个杂志怎么转钱过去？我填了一个费用chart，但是没看到他给我账号。请问出版的前辈们怎么给他转账？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Thu Jul 02 11:57:24 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602161, encodeId=14c26021616c, content=非常奇怪，我一个月内发了4封邮件，带有校稿附件。他都收不到，还让我给他发proof。这是为什么？我163的邮箱没问题啊，我给别的邮箱发都可以啊。我给他发咨询邮件他就说没收到proof。有遇到这样问题的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Sat Jun 13 10:04:10 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123540, encodeId=b76f21235404b, content=快5个月了，怎么还没有消息，中间催了一次，说外审中，时间不确定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221005/d231bd6bc894445e8ddf64ddbeb135f0/a97cb00fc8be4fe49a0630e6db9fcb3e.jpg, createdBy=7dfe8143237, createdName=ms4000002043504686, createdTime=Mon Apr 03 19:36:15 CST 2023, time=2023-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=925369, encodeId=bb0d9253692b, content=终于收到了交费表格，我真的是...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Thu Feb 18 23:38:28 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161585, encodeId=a194216158511, content=07.10投稿，07.12送审，8.23小修，9.04接收，中间修改了4次proof，10.07交了版面费，等online中，虽然是公认的水刊，但是是篇meta分析，能发表就已经很满足了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=01451679623, createdName=叮咚_MH, createdTime=Sun Oct 08 17:55:33 CST 2023, time=2023-10-08, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801171, encodeId=7ec08011e1cc, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：去年10月投的稿今年三四月份小修。后面proof的修改发现编辑会非常仔细的修改文章从作者单位格式问题到内容部分非常认真，觉得IF会再升一升，但确实这个杂志发文量也比较大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Sat Jul 04 11:17:25 CST 2020, time=2020-07-04, status=1, ipAttribution=)]

2020-09-15 1482e854m23(暂无昵称)

审稿速度:3.0
偏重的研究方向：细菌
经验分享：1. 2020.4.20投稿；
2.6月20第一次催稿，两天后回复说在同行评审；
3.8月1号第二次催稿，未收到回复，8月12号直接收到peer-review comments ；要求45天内revision
4.9.8号收到Awaiting response to peer reviewer comments催稿信，于是9,9给杂志社回复了 response to peer reviewer comments
5. 9.14收到acception: We are pleased to inform you that the above manuscript has been provisionally accepted for publication in Experimental and Therapeutic Medicine. The submission should be considered to be formally accepted upon the receipt of proofs.
The manuscript will be sent for production shortly. Once production has been completed, the page proofs of the manuscript will be sent to you with any minor revisions for your consideration.

145 19

展开19条回复

[GetPortalCommentsPageByObjectIdResponse(id=804973, encodeId=700a8049e341, content=出版费已经交了，大概啥时候见刊？有前辈可以告诉一下大概时间吗？网上查不到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Tue Jul 28 23:11:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885503, encodeId=0fc58855039d, content=审稿速度:3.0 偏重的研究方向：细菌 经验分享：1. 2020.4.20投稿； 2.6月20第一次催稿，两天后回复说在同行评审； 3.8月1号第二次催稿，未收到回复，8月12号直接收到peer-review comments ；要求45天内revision 4.9.8号收到Awaiting response to peer reviewer comments催稿信，于是9,9给杂志社回复了 response to peer reviewer comments 5. 9.14收到acception: We are pleased to inform you that the above manuscript has been provisionally accepted for publication in Experimental and Therapeutic Medicine. The submission should be considered to be formally accepted upon the receipt of proofs. The manuscript will be sent for production shortly. Once production has been completed, the page proofs of the manuscript will be sent to you with any minor revisions for your consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e65e5274913, createdName=1482e854m23(暂无昵称), createdTime=Tue Sep 15 16:21:34 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800885, encodeId=b56d80088552, content=请问这个杂志怎么转钱过去？我填了一个费用chart，但是没看到他给我账号。请问出版的前辈们怎么给他转账？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Thu Jul 02 11:57:24 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602161, encodeId=14c26021616c, content=非常奇怪，我一个月内发了4封邮件，带有校稿附件。他都收不到，还让我给他发proof。这是为什么？我163的邮箱没问题啊，我给别的邮箱发都可以啊。我给他发咨询邮件他就说没收到proof。有遇到这样问题的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Sat Jun 13 10:04:10 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123540, encodeId=b76f21235404b, content=快5个月了，怎么还没有消息，中间催了一次，说外审中，时间不确定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221005/d231bd6bc894445e8ddf64ddbeb135f0/a97cb00fc8be4fe49a0630e6db9fcb3e.jpg, createdBy=7dfe8143237, createdName=ms4000002043504686, createdTime=Mon Apr 03 19:36:15 CST 2023, time=2023-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=925369, encodeId=bb0d9253692b, content=终于收到了交费表格，我真的是...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Thu Feb 18 23:38:28 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161585, encodeId=a194216158511, content=07.10投稿，07.12送审，8.23小修，9.04接收，中间修改了4次proof，10.07交了版面费，等online中，虽然是公认的水刊，但是是篇meta分析，能发表就已经很满足了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=01451679623, createdName=叮咚_MH, createdTime=Sun Oct 08 17:55:33 CST 2023, time=2023-10-08, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801171, encodeId=7ec08011e1cc, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：去年10月投的稿今年三四月份小修。后面proof的修改发现编辑会非常仔细的修改文章从作者单位格式问题到内容部分非常认真，觉得IF会再升一升，但确实这个杂志发文量也比较大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Sat Jul 04 11:17:25 CST 2020, time=2020-07-04, status=1, ipAttribution=)]

2020-07-02 蒙住双眼做实验

请问这个杂志怎么转钱过去？我填了一个费用chart，但是没看到他给我账号。请问出版的前辈们怎么给他转账？

105 17

展开17条回复

[GetPortalCommentsPageByObjectIdResponse(id=804973, encodeId=700a8049e341, content=出版费已经交了，大概啥时候见刊？有前辈可以告诉一下大概时间吗？网上查不到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Tue Jul 28 23:11:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885503, encodeId=0fc58855039d, content=审稿速度:3.0 偏重的研究方向：细菌 经验分享：1. 2020.4.20投稿； 2.6月20第一次催稿，两天后回复说在同行评审； 3.8月1号第二次催稿，未收到回复，8月12号直接收到peer-review comments ；要求45天内revision 4.9.8号收到Awaiting response to peer reviewer comments催稿信，于是9,9给杂志社回复了 response to peer reviewer comments 5. 9.14收到acception: We are pleased to inform you that the above manuscript has been provisionally accepted for publication in Experimental and Therapeutic Medicine. The submission should be considered to be formally accepted upon the receipt of proofs. The manuscript will be sent for production shortly. Once production has been completed, the page proofs of the manuscript will be sent to you with any minor revisions for your consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e65e5274913, createdName=1482e854m23(暂无昵称), createdTime=Tue Sep 15 16:21:34 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800885, encodeId=b56d80088552, content=请问这个杂志怎么转钱过去？我填了一个费用chart，但是没看到他给我账号。请问出版的前辈们怎么给他转账？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Thu Jul 02 11:57:24 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602161, encodeId=14c26021616c, content=非常奇怪，我一个月内发了4封邮件，带有校稿附件。他都收不到，还让我给他发proof。这是为什么？我163的邮箱没问题啊，我给别的邮箱发都可以啊。我给他发咨询邮件他就说没收到proof。有遇到这样问题的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Sat Jun 13 10:04:10 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123540, encodeId=b76f21235404b, content=快5个月了，怎么还没有消息，中间催了一次，说外审中，时间不确定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221005/d231bd6bc894445e8ddf64ddbeb135f0/a97cb00fc8be4fe49a0630e6db9fcb3e.jpg, createdBy=7dfe8143237, createdName=ms4000002043504686, createdTime=Mon Apr 03 19:36:15 CST 2023, time=2023-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=925369, encodeId=bb0d9253692b, content=终于收到了交费表格，我真的是...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Thu Feb 18 23:38:28 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161585, encodeId=a194216158511, content=07.10投稿，07.12送审，8.23小修，9.04接收，中间修改了4次proof，10.07交了版面费，等online中，虽然是公认的水刊，但是是篇meta分析，能发表就已经很满足了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=01451679623, createdName=叮咚_MH, createdTime=Sun Oct 08 17:55:33 CST 2023, time=2023-10-08, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801171, encodeId=7ec08011e1cc, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：去年10月投的稿今年三四月份小修。后面proof的修改发现编辑会非常仔细的修改文章从作者单位格式问题到内容部分非常认真，觉得IF会再升一升，但确实这个杂志发文量也比较大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Sat Jul 04 11:17:25 CST 2020, time=2020-07-04, status=1, ipAttribution=)]

2022-02-01 ms2000000130062631

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：基础研究;糖尿病
经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投

70 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=804973, encodeId=700a8049e341, content=出版费已经交了，大概啥时候见刊？有前辈可以告诉一下大概时间吗？网上查不到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Tue Jul 28 23:11:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885503, encodeId=0fc58855039d, content=审稿速度:3.0 偏重的研究方向：细菌 经验分享：1. 2020.4.20投稿； 2.6月20第一次催稿，两天后回复说在同行评审； 3.8月1号第二次催稿，未收到回复，8月12号直接收到peer-review comments ；要求45天内revision 4.9.8号收到Awaiting response to peer reviewer comments催稿信，于是9,9给杂志社回复了 response to peer reviewer comments 5. 9.14收到acception: We are pleased to inform you that the above manuscript has been provisionally accepted for publication in Experimental and Therapeutic Medicine. The submission should be considered to be formally accepted upon the receipt of proofs. The manuscript will be sent for production shortly. Once production has been completed, the page proofs of the manuscript will be sent to you with any minor revisions for your consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e65e5274913, createdName=1482e854m23(暂无昵称), createdTime=Tue Sep 15 16:21:34 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800885, encodeId=b56d80088552, content=请问这个杂志怎么转钱过去？我填了一个费用chart，但是没看到他给我账号。请问出版的前辈们怎么给他转账？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Thu Jul 02 11:57:24 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602161, encodeId=14c26021616c, content=非常奇怪，我一个月内发了4封邮件，带有校稿附件。他都收不到，还让我给他发proof。这是为什么？我163的邮箱没问题啊，我给别的邮箱发都可以啊。我给他发咨询邮件他就说没收到proof。有遇到这样问题的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Sat Jun 13 10:04:10 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123540, encodeId=b76f21235404b, content=快5个月了，怎么还没有消息，中间催了一次，说外审中，时间不确定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221005/d231bd6bc894445e8ddf64ddbeb135f0/a97cb00fc8be4fe49a0630e6db9fcb3e.jpg, createdBy=7dfe8143237, createdName=ms4000002043504686, createdTime=Mon Apr 03 19:36:15 CST 2023, time=2023-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=925369, encodeId=bb0d9253692b, content=终于收到了交费表格，我真的是...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Thu Feb 18 23:38:28 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161585, encodeId=a194216158511, content=07.10投稿，07.12送审，8.23小修，9.04接收，中间修改了4次proof，10.07交了版面费，等online中，虽然是公认的水刊，但是是篇meta分析，能发表就已经很满足了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=01451679623, createdName=叮咚_MH, createdTime=Sun Oct 08 17:55:33 CST 2023, time=2023-10-08, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801171, encodeId=7ec08011e1cc, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：去年10月投的稿今年三四月份小修。后面proof的修改发现编辑会非常仔细的修改文章从作者单位格式问题到内容部分非常认真，觉得IF会再升一升，但确实这个杂志发文量也比较大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Sat Jul 04 11:17:25 CST 2020, time=2020-07-04, status=1, ipAttribution=)]

2020-06-13 蒙住双眼做实验

非常奇怪，我一个月内发了4封邮件，带有校稿附件。他都收不到，还让我给他发proof。这是为什么？我163的邮箱没问题啊，我给别的邮箱发都可以啊。我给他发咨询邮件他就说没收到proof。有遇到这样问题的吗

71 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=804973, encodeId=700a8049e341, content=出版费已经交了，大概啥时候见刊？有前辈可以告诉一下大概时间吗？网上查不到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Tue Jul 28 23:11:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885503, encodeId=0fc58855039d, content=审稿速度:3.0 偏重的研究方向：细菌 经验分享：1. 2020.4.20投稿； 2.6月20第一次催稿，两天后回复说在同行评审； 3.8月1号第二次催稿，未收到回复，8月12号直接收到peer-review comments ；要求45天内revision 4.9.8号收到Awaiting response to peer reviewer comments催稿信，于是9,9给杂志社回复了 response to peer reviewer comments 5. 9.14收到acception: We are pleased to inform you that the above manuscript has been provisionally accepted for publication in Experimental and Therapeutic Medicine. The submission should be considered to be formally accepted upon the receipt of proofs. The manuscript will be sent for production shortly. Once production has been completed, the page proofs of the manuscript will be sent to you with any minor revisions for your consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e65e5274913, createdName=1482e854m23(暂无昵称), createdTime=Tue Sep 15 16:21:34 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800885, encodeId=b56d80088552, content=请问这个杂志怎么转钱过去？我填了一个费用chart，但是没看到他给我账号。请问出版的前辈们怎么给他转账？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Thu Jul 02 11:57:24 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602161, encodeId=14c26021616c, content=非常奇怪，我一个月内发了4封邮件，带有校稿附件。他都收不到，还让我给他发proof。这是为什么？我163的邮箱没问题啊，我给别的邮箱发都可以啊。我给他发咨询邮件他就说没收到proof。有遇到这样问题的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Sat Jun 13 10:04:10 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123540, encodeId=b76f21235404b, content=快5个月了，怎么还没有消息，中间催了一次，说外审中，时间不确定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221005/d231bd6bc894445e8ddf64ddbeb135f0/a97cb00fc8be4fe49a0630e6db9fcb3e.jpg, createdBy=7dfe8143237, createdName=ms4000002043504686, createdTime=Mon Apr 03 19:36:15 CST 2023, time=2023-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=925369, encodeId=bb0d9253692b, content=终于收到了交费表格，我真的是...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Thu Feb 18 23:38:28 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161585, encodeId=a194216158511, content=07.10投稿，07.12送审，8.23小修，9.04接收，中间修改了4次proof，10.07交了版面费，等online中，虽然是公认的水刊，但是是篇meta分析，能发表就已经很满足了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=01451679623, createdName=叮咚_MH, createdTime=Sun Oct 08 17:55:33 CST 2023, time=2023-10-08, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801171, encodeId=7ec08011e1cc, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：去年10月投的稿今年三四月份小修。后面proof的修改发现编辑会非常仔细的修改文章从作者单位格式问题到内容部分非常认真，觉得IF会再升一升，但确实这个杂志发文量也比较大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Sat Jul 04 11:17:25 CST 2020, time=2020-07-04, status=1, ipAttribution=)]

2023-04-03 ms4000002043504686 来自山东省

快5个月了，怎么还没有消息，中间催了一次，说外审中，时间不确定

39 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=804973, encodeId=700a8049e341, content=出版费已经交了，大概啥时候见刊？有前辈可以告诉一下大概时间吗？网上查不到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Tue Jul 28 23:11:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885503, encodeId=0fc58855039d, content=审稿速度:3.0 偏重的研究方向：细菌 经验分享：1. 2020.4.20投稿； 2.6月20第一次催稿，两天后回复说在同行评审； 3.8月1号第二次催稿，未收到回复，8月12号直接收到peer-review comments ；要求45天内revision 4.9.8号收到Awaiting response to peer reviewer comments催稿信，于是9,9给杂志社回复了 response to peer reviewer comments 5. 9.14收到acception: We are pleased to inform you that the above manuscript has been provisionally accepted for publication in Experimental and Therapeutic Medicine. The submission should be considered to be formally accepted upon the receipt of proofs. The manuscript will be sent for production shortly. Once production has been completed, the page proofs of the manuscript will be sent to you with any minor revisions for your consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e65e5274913, createdName=1482e854m23(暂无昵称), createdTime=Tue Sep 15 16:21:34 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800885, encodeId=b56d80088552, content=请问这个杂志怎么转钱过去？我填了一个费用chart，但是没看到他给我账号。请问出版的前辈们怎么给他转账？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Thu Jul 02 11:57:24 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602161, encodeId=14c26021616c, content=非常奇怪，我一个月内发了4封邮件，带有校稿附件。他都收不到，还让我给他发proof。这是为什么？我163的邮箱没问题啊，我给别的邮箱发都可以啊。我给他发咨询邮件他就说没收到proof。有遇到这样问题的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Sat Jun 13 10:04:10 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123540, encodeId=b76f21235404b, content=快5个月了，怎么还没有消息，中间催了一次，说外审中，时间不确定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221005/d231bd6bc894445e8ddf64ddbeb135f0/a97cb00fc8be4fe49a0630e6db9fcb3e.jpg, createdBy=7dfe8143237, createdName=ms4000002043504686, createdTime=Mon Apr 03 19:36:15 CST 2023, time=2023-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=925369, encodeId=bb0d9253692b, content=终于收到了交费表格，我真的是...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Thu Feb 18 23:38:28 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161585, encodeId=a194216158511, content=07.10投稿，07.12送审，8.23小修，9.04接收，中间修改了4次proof，10.07交了版面费，等online中，虽然是公认的水刊，但是是篇meta分析，能发表就已经很满足了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=01451679623, createdName=叮咚_MH, createdTime=Sun Oct 08 17:55:33 CST 2023, time=2023-10-08, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801171, encodeId=7ec08011e1cc, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：去年10月投的稿今年三四月份小修。后面proof的修改发现编辑会非常仔细的修改文章从作者单位格式问题到内容部分非常认真，觉得IF会再升一升，但确实这个杂志发文量也比较大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Sat Jul 04 11:17:25 CST 2020, time=2020-07-04, status=1, ipAttribution=)]

2021-02-18 悦悦是超人🦸‍♀️

终于收到了交费表格，我真的是....

132 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=804973, encodeId=700a8049e341, content=出版费已经交了，大概啥时候见刊？有前辈可以告诉一下大概时间吗？网上查不到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Tue Jul 28 23:11:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885503, encodeId=0fc58855039d, content=审稿速度:3.0 偏重的研究方向：细菌 经验分享：1. 2020.4.20投稿； 2.6月20第一次催稿，两天后回复说在同行评审； 3.8月1号第二次催稿，未收到回复，8月12号直接收到peer-review comments ；要求45天内revision 4.9.8号收到Awaiting response to peer reviewer comments催稿信，于是9,9给杂志社回复了 response to peer reviewer comments 5. 9.14收到acception: We are pleased to inform you that the above manuscript has been provisionally accepted for publication in Experimental and Therapeutic Medicine. The submission should be considered to be formally accepted upon the receipt of proofs. The manuscript will be sent for production shortly. Once production has been completed, the page proofs of the manuscript will be sent to you with any minor revisions for your consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e65e5274913, createdName=1482e854m23(暂无昵称), createdTime=Tue Sep 15 16:21:34 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800885, encodeId=b56d80088552, content=请问这个杂志怎么转钱过去？我填了一个费用chart，但是没看到他给我账号。请问出版的前辈们怎么给他转账？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Thu Jul 02 11:57:24 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602161, encodeId=14c26021616c, content=非常奇怪，我一个月内发了4封邮件，带有校稿附件。他都收不到，还让我给他发proof。这是为什么？我163的邮箱没问题啊，我给别的邮箱发都可以啊。我给他发咨询邮件他就说没收到proof。有遇到这样问题的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Sat Jun 13 10:04:10 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123540, encodeId=b76f21235404b, content=快5个月了，怎么还没有消息，中间催了一次，说外审中，时间不确定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221005/d231bd6bc894445e8ddf64ddbeb135f0/a97cb00fc8be4fe49a0630e6db9fcb3e.jpg, createdBy=7dfe8143237, createdName=ms4000002043504686, createdTime=Mon Apr 03 19:36:15 CST 2023, time=2023-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=925369, encodeId=bb0d9253692b, content=终于收到了交费表格，我真的是...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Thu Feb 18 23:38:28 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161585, encodeId=a194216158511, content=07.10投稿，07.12送审，8.23小修，9.04接收，中间修改了4次proof，10.07交了版面费，等online中，虽然是公认的水刊，但是是篇meta分析，能发表就已经很满足了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=01451679623, createdName=叮咚_MH, createdTime=Sun Oct 08 17:55:33 CST 2023, time=2023-10-08, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801171, encodeId=7ec08011e1cc, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：去年10月投的稿今年三四月份小修。后面proof的修改发现编辑会非常仔细的修改文章从作者单位格式问题到内容部分非常认真，觉得IF会再升一升，但确实这个杂志发文量也比较大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Sat Jul 04 11:17:25 CST 2020, time=2020-07-04, status=1, ipAttribution=)]

2023-10-08 叮咚_MH 来自黑龙江省

07.10投稿，07.12送审，8.23小修，9.04接收，中间修改了4次proof，10.07交了版面费，等online中，虽然是公认的水刊，但是是篇meta分析，能发表就已经很满足了。

35 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=804973, encodeId=700a8049e341, content=出版费已经交了，大概啥时候见刊？有前辈可以告诉一下大概时间吗？网上查不到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Tue Jul 28 23:11:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885503, encodeId=0fc58855039d, content=审稿速度:3.0 偏重的研究方向：细菌 经验分享：1. 2020.4.20投稿； 2.6月20第一次催稿，两天后回复说在同行评审； 3.8月1号第二次催稿，未收到回复，8月12号直接收到peer-review comments ；要求45天内revision 4.9.8号收到Awaiting response to peer reviewer comments催稿信，于是9,9给杂志社回复了 response to peer reviewer comments 5. 9.14收到acception: We are pleased to inform you that the above manuscript has been provisionally accepted for publication in Experimental and Therapeutic Medicine. The submission should be considered to be formally accepted upon the receipt of proofs. The manuscript will be sent for production shortly. Once production has been completed, the page proofs of the manuscript will be sent to you with any minor revisions for your consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e65e5274913, createdName=1482e854m23(暂无昵称), createdTime=Tue Sep 15 16:21:34 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800885, encodeId=b56d80088552, content=请问这个杂志怎么转钱过去？我填了一个费用chart，但是没看到他给我账号。请问出版的前辈们怎么给他转账？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Thu Jul 02 11:57:24 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602161, encodeId=14c26021616c, content=非常奇怪，我一个月内发了4封邮件，带有校稿附件。他都收不到，还让我给他发proof。这是为什么？我163的邮箱没问题啊，我给别的邮箱发都可以啊。我给他发咨询邮件他就说没收到proof。有遇到这样问题的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Sat Jun 13 10:04:10 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123540, encodeId=b76f21235404b, content=快5个月了，怎么还没有消息，中间催了一次，说外审中，时间不确定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221005/d231bd6bc894445e8ddf64ddbeb135f0/a97cb00fc8be4fe49a0630e6db9fcb3e.jpg, createdBy=7dfe8143237, createdName=ms4000002043504686, createdTime=Mon Apr 03 19:36:15 CST 2023, time=2023-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=925369, encodeId=bb0d9253692b, content=终于收到了交费表格，我真的是...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Thu Feb 18 23:38:28 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161585, encodeId=a194216158511, content=07.10投稿，07.12送审，8.23小修，9.04接收，中间修改了4次proof，10.07交了版面费，等online中，虽然是公认的水刊，但是是篇meta分析，能发表就已经很满足了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=01451679623, createdName=叮咚_MH, createdTime=Sun Oct 08 17:55:33 CST 2023, time=2023-10-08, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801171, encodeId=7ec08011e1cc, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：去年10月投的稿今年三四月份小修。后面proof的修改发现编辑会非常仔细的修改文章从作者单位格式问题到内容部分非常认真，觉得IF会再升一升，但确实这个杂志发文量也比较大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Sat Jul 04 11:17:25 CST 2020, time=2020-07-04, status=1, ipAttribution=)]

2020-09-23 ms8000000548825590

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：颗粒物;毒理
经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？

139 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=804973, encodeId=700a8049e341, content=出版费已经交了，大概啥时候见刊？有前辈可以告诉一下大概时间吗？网上查不到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Tue Jul 28 23:11:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885503, encodeId=0fc58855039d, content=审稿速度:3.0 偏重的研究方向：细菌 经验分享：1. 2020.4.20投稿； 2.6月20第一次催稿，两天后回复说在同行评审； 3.8月1号第二次催稿，未收到回复，8月12号直接收到peer-review comments ；要求45天内revision 4.9.8号收到Awaiting response to peer reviewer comments催稿信，于是9,9给杂志社回复了 response to peer reviewer comments 5. 9.14收到acception: We are pleased to inform you that the above manuscript has been provisionally accepted for publication in Experimental and Therapeutic Medicine. The submission should be considered to be formally accepted upon the receipt of proofs. The manuscript will be sent for production shortly. Once production has been completed, the page proofs of the manuscript will be sent to you with any minor revisions for your consideration., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e65e5274913, createdName=1482e854m23(暂无昵称), createdTime=Tue Sep 15 16:21:34 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800885, encodeId=b56d80088552, content=请问这个杂志怎么转钱过去？我填了一个费用chart，但是没看到他给我账号。请问出版的前辈们怎么给他转账？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Thu Jul 02 11:57:24 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602161, encodeId=14c26021616c, content=非常奇怪，我一个月内发了4封邮件，带有校稿附件。他都收不到，还让我给他发proof。这是为什么？我163的邮箱没问题啊，我给别的邮箱发都可以啊。我给他发咨询邮件他就说没收到proof。有遇到这样问题的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/25/ca372455cb9f9d85f9c8523ca20b22fd.jpg, createdBy=96f35086424, createdName=蒙住双眼做实验, createdTime=Sat Jun 13 10:04:10 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123540, encodeId=b76f21235404b, content=快5个月了，怎么还没有消息，中间催了一次，说外审中，时间不确定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221005/d231bd6bc894445e8ddf64ddbeb135f0/a97cb00fc8be4fe49a0630e6db9fcb3e.jpg, createdBy=7dfe8143237, createdName=ms4000002043504686, createdTime=Mon Apr 03 19:36:15 CST 2023, time=2023-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=925369, encodeId=bb0d9253692b, content=终于收到了交费表格，我真的是...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Thu Feb 18 23:38:28 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161585, encodeId=a194216158511, content=07.10投稿，07.12送审，8.23小修，9.04接收，中间修改了4次proof，10.07交了版面费，等online中，虽然是公认的水刊，但是是篇meta分析，能发表就已经很满足了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=01451679623, createdName=叮咚_MH, createdTime=Sun Oct 08 17:55:33 CST 2023, time=2023-10-08, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：颗粒物;毒理 经验分享：已经接收五个多月了，目前还是In production，也没通知缴费，发邮件也没回复，有同行遇到类似问题吗？什么情况？大约多久缴费以及多久可以在线发表呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801171, encodeId=7ec08011e1cc, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：去年10月投的稿今年三四月份小修。后面proof的修改发现编辑会非常仔细的修改文章从作者单位格式问题到内容部分非常认真，觉得IF会再升一升，但确实这个杂志发文量也比较大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/8819967a0d3c4de8a9fc93ef11105dc3/d924cfea469f4f6ab261692ad6ea572e.jpg, createdBy=e4895130301, createdName=悦悦是超人🦸‍♀️, createdTime=Sat Jul 04 11:17:25 CST 2020, time=2020-07-04, status=1, ipAttribution=)]

2020-07-04 悦悦是超人🦸‍♀️

审稿速度:6.0 | 投稿命中率:75.0
经验分享：去年10月投的稿今年三四月份小修。后面proof的修改发现编辑会非常仔细的修改文章从作者单位格式问题到内容部分非常认真，觉得IF会再升一升，但确实这个杂志发文量也比较大。

121 8

展开8条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务